Genetic determinants of arterial thrombosis

Bailliere's Best Practice and Research in Clinical Haematology

Volumn 12, Issue 3, 1999, Pages 505-532

  Grant, Peter J ^a   Humphries, Steven E ^b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Coagulation; Fibrinolysis; Genes; Myocardial infarction; Platelets; Polymorphisms

Indexed keywords

BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 7; FIBRINOGEN; FIBRINOGEN RECEPTOR; GLYCOPROTEIN; HEMOSTATIC AGENT; PLASMINOGEN ACTIVATOR INHIBITOR;

ARTERY THROMBOSIS; CEREBROVASCULAR DISEASE; ENVIRONMENTAL FACTOR; GENDER; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEART INFARCTION; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; REVIEW; SMOKING;

EID: 0033509462     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1053/beha.1999.0038     Document Type: Article

References (185)

1. Meade T W, Imeson J, Stirling Y. Effects of changes in smoking and other characteristics on clotting factors and risk of ischaemic heart disease. Lancet. ii:1987;986-988.
2. Johnson O, Mellbring G, Neilson T. Defective fibrinolysis in survivors of myocardial infarction. International Journal of Cardiology. 6:1984;380-382.
3. Wilhelmsen L, Svärdsudd K, Korsan-Bengtsen K. Fibrinogen as a risk factor for stroke and myocardial infarction. New England Journal of Medicine. 311:1984;501-505.
4. Hamsten A, Wiman B, de Faire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator inhibitor in young survivors of myocardial infarcation. New England Journal of Medicine. 313:1985;1557-1563.
5. Hamsten A, de Faire U, Walldius G. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. ii:1987;3-9.
6. Paramo J A, Colucci M, Collen D, van de Werf F. Plasminogen activator inhibitor in the blood of patients with coronary artery disease. British Medical Journal. 291:1985;573-574.
7. Stone M C, Thorpe J M. Plasma fibrinogens - a major coronary risk factor. Journal of the Royal College of General Practitioners. 35:1985;565-569.
8. Meade T W, Mellows S, Brozovic M. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet. ii:1986;533-537.
9. Kannell W B, Wolf P A, Castelli W P, D'Agostino R B. Fibrinogen and risk of cardiovascular disease: the Framingham Study. Journal of the American Medical Association. 258:1987;1183-1186.
10. Aznar J, Estilles A, Tormo G. Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease. British Heart Journal. 59:1988;535-541.
11. Green F R, Humphries S E. Control of plasma fibrinogen levels. Baillière's Clinical Haematology. 2:1989;945-959.
12. Folsom A R, Wu K K, Davis C E. Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors. Atherosclerosis. 91:1991;191-205.
13. Dawson S, Henney A. The status of PAI-1 as a risk factor for arterial and thrombotic disease: a review. Atherosclerosis. 95:1992;105-117.
14. Humphries S E, Cook M, Dubowitz M. Role of genetic variation at the fibrinogen locus in determination of plasma fibrinogen concentrations. Lancet. i:1987;1452-1455.
15. Dawson S, Hamsten A, Wiman B. Genetic variation at the plasminogen activator inhibitor 1 locus is associated with altered levels of plasminogen activator inhibitors-1 activity. Arteriosclerosis and Thrombosis. 11:1991;183-190.
16. Green F, Kelleher C, Wilkes H. A common genetic polymorphism associated with lower coagulation factor VII levels in healthy individuals. Arteriosclerosis and Thrombosis. 11:1991;540-546.
17. Green F, Hamsten A, Blombäck M, Humphries S. The role of b-fibrinogen genotype in determining plasma fibrinogen levels in young survivors of myocardial infarction and healthy controls from Sweden. Thrombosis and Haemostasis. 70:1993;915-920.
18. Thomas A, Kelleher C, Green F. Variation in the promoter region of the b-fibrinogen gene is associated with plasma fibrinogen levels in smokers and non-smokers. Thrombosis and Haemostasis. 65:1991;487-490.
19. Lane A, Cruickshank J K, Stewart J. Genetic and environmental determinants of factor VII coagulant activity in different ethnic groups at differing risk of coronary heart disease. Atherosclerosis. 94:1992;43-50.
20. Dawson S J, Wiman B, Hamsten A. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitory (PAI-1) gene respond differently to IL-1 in HepG2 cells. Journal of Biological Chemistry. 268:1993;10739-10745.
21. Kohler H P, Stickland M H, Ossei-Gerning N. Association of a common polymorphism in the factor XIII gene with myocardial infarction. Thrombosis and Haemostasis. 79:1998;8-13.
22. Weiss E J, Bray P F, Tayback M. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. New England Journal of Medicine. 334:1996;1090-1094.
23. Kohler H P, Ariens R AS, Whitaker P, Grant P J. A common coding polymorphism in the Factor XIII A-subunit gene (FXIIIVal34Leu) affects cross linking activity. Thrombosis and Haemostasis. 80:1998;704.
24. Anwar R, Gallivan L, Edmonds S D, Markham A F. Genotype/phenotype correlations for coagulation factor XIII: specific normal polymorphisms are associated with high or low factor XIII specific activity. Blood. 93:1999;897-905.
25. Fey G H, Fuller G M. Regulation of acute phase gene expression by inflammatory mediators. Molecular Biology and Medicine. 4:1987;323-338.
26. Meade T W, Biozonic M, Chakrabarti R. An epidemiological study of the haemostatic and other effects of oral contraception. British Journal of Haematology. 34:1976;353-364.
27. Bonnar, J, Haemostasis in pregnancy and coagulation disorders, MacDonald, R, R, Scientific Basis of Obstetrics and Gynaecology, 249, 273, Edinburgh, Churchill Livingstone, 1978.
28. Balleisen L, Bailey J, Epping P H. Epidemiology study on factor VII, factor VIII and fibrinogen in an industrial sample. I. Baseline data in the relation to age, gender, body weight, smoking, alcohol, pill using and menopause. Thrombosis and Haemostasis. 54:1985;475-479.
29. Meade T W, North W RS. Population based distributions of haemostatic variables. British Medical Bulletin. 33:1977;283-288.
30. Meade T W, Chakrabarti R, Haines A P. Characteristics affecting fibrinolytic activity and plasma fibrinogen concentrations. British Medical Journal. 1:1979;153-156.
31. Abbot R D, Yin Yin M A, Reed D M, Yano K. Risk of stroke in male cigarette smokers. New England Journal of Medicine. 315:1986;717-720.
32. Dalmon J, Laurent M, Courtois G. The human b fibrinogen promoter contains hepatocyte nuclear factor 1-dependent interleukin-6-responsive element. Molecular Cell Biology. 13:1993;1183-1193.
33. Thompson S G, Martin J C, Meade T W. Sources of variability in coagulation factor assays. Thrombosis and Haemostasis. 58:1987;1073-1077.
34. Henschen A, McDonagh J. Fibrinogen, fibrin and factor XIII. Zwaal R FD, Henker H C. Blood Coagulation. 1986;171-239 Elsevier, Amsterdam.
35. Kant J A, Furnace A J Jr, Saxe D. Evolution and organisation of the fibrinogen locus on chromosome 4: gene duplication accompanied by transcription and inversion. Proceedings of the National Academy of Sciences of the USA. 82:1985;2344-2348.
36. Yu S, Sher B, Kudryk B, Redman C M. Intracellular assembly of human fibrinogen. Journal of Biological Chemistry. 258:1983;13407-13410.
37. Yu S, Sher B, Redman C. A scheme for the intracellular assembly of human fibrinogen. Lane D A, Henshen A, Jasani M K. Fibrinogen, Fibrin Formation and Fibrinolysis. 1986;3-13 Walter de Gruyter, Berlin.
38. Ray S M, Mukhopadtyay G, Redman C M. Regulation of fibrinogen assembly. Transcription of HepG2 cells with Bb cDNA specifically enhances synthesis of the three component chains of fibrinogen. Journal of Biological Chemistry. 265:1990;6389-6393.
39. Courtois G, Morgan J G, Campbell L A. Interaction of a liver-specific nuclear factor with the fibrinogen and a-1-antitrypsin promoters. Science. 238:1987;688-692.
40. Huber P, Laurent M, Dalmon J. Human fibrinogen gene expression. Upstream sequences involved in its tissue specific expression and its dexamethasone and interleukin-6 stimulation. Journal of Biological Chemistry. 265:1990;5695-5701.
41. Hamsten A, Iselius L, de Faire U, Blomback M. Genetic and cultural inheritance of plasma fibrinogen concentration. Lancet. ii:1987;988-990.
42. Berg K, Kierulf P. DNA polymorphisms at fibrinogen loci and plasma fibrinogen concentration. Clinical Genetics. 36:1992;229-235.
43. Reed T, Tracy R P, Fabsitz R R. Minimal genetic influences on plasma fibrinogen level in adult males in the NHLBI twin study. Clinical Genetics. 45:1994;71-77.
44. Friedlander Y, Elkana Y, Sinnreich R, Kark J D. Genetic and environmental sources of fibrinogen variability in Israeli families: the Kibbutzim Family Study. American Journal of Human Genetics. 56:1995;1194-1206.
45. Thomas A, Lamlum H, Humphries S, Green F. Linkage disequilibrium across the fibrinogen locus as shown by five genetic polymorphisms, G/A-455 (HaeIII), C/T-148 (HindIII/AluI), T/G-1689 (AvaII), and Bc1I (b-fibrinogen) and TaqI (a-fibrinogen), and their detection by PCR. Human Mutation. 3:1994;79-81.
46. Humphries S E, Thomas A, Montgomery H E. Gene-environment interaction in the determination of plasma levels of fibrinogen. Fibrinolysis and Proteolysis. 11:1997;3-7.
47. Conner J M, Fowkes F GR, Wood J. Genetic variation at fibrinogen loci and plasma fibrinogen levels. Journal of Medical Genetics. 29:1992;480-482.
48. Scarabin P Y, Bara L, Ricard S. Genetic variation at the b-fibrinogen locus in relation to plasma fibrinogen concentrations and risk of myocardial infarction. The ECTIM study. Arteriosclerosis and Thrombosis. 13:1993;886-891.
49. Humphries S E, Ye S, Talmud P. European Atherosclerosis Research Study: genotype at the fibrinogen locus (G-455-A beta-gene) is associated with differences in plasma fibrinogen levels in young men and women from different regions in Europe. Evidence for gender-genotype-environment interaction. Arteriosclerosis, Thrombosis and Vascular Biology. 15:1995;96-104.
50. Thomas A E, Kelleher C C, Green F, Humphries S E. Association of genetic variation at the -fibrinogen gene locus and plasma fibrinogen levels: interaction between allele frequency of the G/A-455 polymorphism, age, smoking. Clinical Genetics. 50:1996;184-190.
51. Lane A, Humphries S E, Green F R. Effect on transcription of two common genetic polymorphisms adjacent to the promoter region of the B-fibrinogen gene. Thrombosis and Haemostasis. 69:1993;1539.
52. Behague I, Poirier O, Nicaud V. β-fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction. The ECTIM study. Circulation. 93:1996;440-449.
53. Henry J A, Bolla M, Osmond C. The effects of genotype and infant weight on adult plasma levels of fibrinogen, factor VII, and LDL cholesterol are additive. Journal of Medical Genetics. 34:1997;553-558.
54. Montgomery H E, Clarkson P, Nwose O M. The acute rise in serum fibrinogen concentration with exercise is influenced by the G-453-A polymorphism of the beta-fibrinogen gene. Arteriosclerosis, Thrombosis and Vascular Biology. 16:1996;386-391.
55. Tybjaerg-Hansen A, Agerholm-Larsen B, Humphries S E. A common mutation (G-455→A) in the beta-fibrinogen promoter is an independent predistor of plasma fibrinogen, but not of ischemic heart disease. A study of 9,127 individuals based on the Copenhagen City Heart Study. Journal of Clinical Investigation. 99:1997;3034-3039.
56. Biasucci L M, Vitelli A, Liuzzo G. Elevated levels of IL-6 in unstable angina. Circulation. 94:1996;874-877.
57. Sturk A, Hack C E, Aarden L A. Interleukin 6 release and the acute phase reaction in patients with acute myocardial infarction. Journal of Laboratory and Clinical Medicine. 119:1992;574-579.
58. Meade T W, Ruddock V, Stirling Y. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet. 342:1993;1076-1079.
59. Gardemann A, Schwartz O, Haberbosch W. Positive association of the Bbβfibrinogen H1/H2 gene variation to basal fibrinogen levels and to the increase in fibrinogen concentration during acute phase reaction but not to coronary artery disease and myocardial infarction. Thrombosis and Haemostasis. 77:1997;1120-1126.
60. Fowkes F GR, Conner J M, Smith F B. Fibrinogen genotype and risk of peripheral atherosclerosis. Lancet. 339:1992;693-696.
61. Carter A M, Mansfield M W, Stickland M H, Grant P J. Beta-fibrinogen gene -455 G/A polymorphism and fibrinogen levels. Risk factors for coronary artery disease in subjects with NIDDM. Diabetes Care. 19:1996;1265-1268.
62. de Maat M P, Kastelein J J, Jukema J W. -455G/A polymorphism of the β-fibrinogen gene is associated with the progression of coronary atherosclerosis in symptomatic men: proposed role for an acute-phase reaction pattern of fibrinogen REGRESS group. Arteriosclerosis, Thrombosis and Vascular Biology. 18:1998;265-271.
63. Zito F, Di Castelnuovo A, Amore C. Bc1 I polymorphism in the fibrinogen β-chain gene is associated with the risk of familial myocardial infarction by increasing plasma fibrinogen levels. A case control study in a sample of GISSI-2 patients. Arteriosclerosis, Thrombosis and Vascular Biology. 17:1997;3489-3494.
64. Schmidt H, Schmidt R, Niederkorn K. β-fibrinogen gene polymorphism (C148T) is associated with carotid atherosclerosis: results of the Austrian Stroke Prevention Study. Arteriosclerosis, Thrombosis and Vascular Biology. 18:1998;487-492.
65. Carter A M, Catto A J, Bamford J M, Grant P J. Gender-specific associations of the fibrinogen Bβ448 polymorphism, fibrinogen levels, and acute cerebrovascular disease. Arteriosclerosis, Thrombosis and Vascular Biology. 17:1997;589-594.
66. Nishiuma S, Kario K, Yakushijin K. Genetic variation in the promoter region of the β-fibrinogen gene is associated with ischemic stroke in a Japanese population. Blood Coagulation and Fibrinolysis. 9:1998;373-379.
67. Baumann R E, Henschen A H. Human fibrinogen polymorphic site analysis by restriction endonuclease digestion and allele-specific polymerase chain reaction amplification: identification of polymorphisms at position Aα312 and Bβ448. Blood. 82:1996;2117-2124.
68. Muszbek L, Adany R, Mikkola H. Novel aspects of blood coagulation factor XIII, I: structure, distribution, activation and function. Critical Reviews in Clinical Laboratory Science. 33:1996;357-421.
69. Credo R B, Curtis C G, Lorand L. Alpha-chain domain of fibrinogen controls generation of fibrinoligase (factor XIIIa): calcium ion regulatory aspects. Biochemistry. 20:1981;3770-3778.
70. Curran J M, Evans A, Arveiler D. The a-fibrinogen T/A 312 polymorphism in the ECTIM study. Thrombosis and Haemostasis. 79:1998;1057-1058.
71. Carter A M, Catto A J, Grant P J. Association of the a-fibrinogen Thr 312Ala polymorphism with post stroke mortality in subjects with atrial fibrillation. Circulation. 99:1999;2423-2426.
72. Broze G J Jr, Majerus P W. Purification and properties of human coagulation Factor VII. Journal of Biological Chemistry. 255:1980;1242-1247.
73. Mitropoulos K A, Esnouf M P. The prothrombin activation peptide regulates synthesis of the vitamin K-dependent proteins in the rabbit. Thrombosis Research. 57:1990;541-545.
74. Heinrich J, Balleisen L, Schulte H. Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men. Arteriosclerosis and Thrombosis. 14:1994;54-59.
75. Smith F B, Lee A J, Fowkes F GR. Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study. Arteriosclerosis, Thrombosis and Vascular Biology. 17:1997;3321-3325.
76. Lane A, Green F, Scarabin P Y. Factor VII Arg/Gln353 polymorphism determines factor VII coagulant activity in patients with myocardial infarction (MI) and control subjects in Belfast and in France but is not a strong indicator of AMI risk in the ECTIM study. Atherosclerosis. 119:1996;119-127.
77. Hoffman C J, Miller R H, Lawson W E, Hultin M B. Elevation of factor VII activity and mass in young adults at risk of ischemic heart disease. Journal of the American College of Cardiology. 14:1989;941-946.
78. Heywood D M, Ossei-Gerning N, Grant P J. Association of factor VII:C levels with environmental and genetic factors in patients with ischaemic heart disease and coronary atheroma characterised by angiography. Thrombosis and Haemostasis. 76:1996;161-165.
79. Vaziri N D, Kennedy S C, Kennedy D, Gonzales E. Coagulation, fibrinolytic, and inhibitory proteins in acute myocardial infarction. American Journal of Medicine. 93:1992;651.
80. Simpson H CR, Meade T W, Stirling Y. Hypertriglyceridaemia and hypercoagulability. Lancet. i:1983;786-790.
81. Miller G J, Walter S J, Stirling Y. Assay of factor VII activity by two techniques: evidence for increased conversion of VII to a-VIIa in hyperlipidaemia, with possible implications for ischaemic heart disease. British Journal of Haematology. 59:1985;249-258.
82. Miller G J, Martin J C, Webster J. Association between dietary fat intake and plasma factor VII coagulant activity, a predictor of cardiovascular mortality. Atherosclerosis. 60:1986;269-277.
83. Miller G J, Cruickshank J K, Ellis L J. Fat consumption and factor VII coagulant activity in middle-aged men: an association between a dietary and thrombogenic coronary risk factor. Atherosclerosis. 78:1989;19-24.
84. Mitropoulos K A, Esnouf M P. Turnover of factor X and of prothrombin in rabbits fed on a standard or cholesterol-supplemented diet. Biochemical Journal. 244:1987;263-269.
85. Mitropoulos K A, Esnouf M P, Meade T W. Increased factor VII coagulant activity in the rabbit following diet-induced hypercholesterolaemia. Atherosclerosis. 63:1987;43-48.
86. Mitropoulos K A, Miller G J, Reeves B EA. Factor VII coagulant activity is strongly associated with the plasma concentration of large lipoprotein particles in middle-aged men. Atherosclerosis. 76:1989;203-208.
87. Castelli W P. The triglyceride issue: a view from Framingham. American Heart Journal. 112:1986;432-437.
88. Mitropoulos K A, Esnouf M P. The autoactivation of factor XII in the presence of long-chain fatty acids - a comparison with the potency of sulphatides and dextran sulphate. Thrombosis and Haemostatis. 66:1991;446-452.
89. Mitropoulos K A, Miller G J, Watts G F, Durrington P N. Lipolysis of triglyceride-rich lipoproteins activates coagulant factor XII: a study in familial lipoprotein-lipase deficiency. Atherosclerosis. 95:1992;119-125.
90. Assmann M D, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). American Journal of Cardiology. 70:1992;733-737.
91. Manninen V, Tenkanen L, Koskinen P. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Circulation. 85:1992;37-45.
92. Pfeiffer R A, Ott R, Taben K D. Clotting factors VII and X as useful markers of terminal deletion of chromosome 13. Human Genetics. 69:1985;192.
93. O'Hara P J, Grant F J, Haldeman B A. Nucleotide sequence of the gene coding for human factor VII, a vitamin K-dependent protein participating in blood coagulation. Proceedings of the National Academy of Sciences of the USA. 84:1987;5158-5162.
94. Marchetti G, Patracchini P, Papaschini M. A polymorphism in the 5′ region of coagulation factor VII gene (F7) caused by an inserted decanucleotide. Human Genetics. 90:1993;575-576.
95. Bernardi F, Marchetti G, Pinotti M. Factor VII gene polymorphisms contribute about one third of the factor VII level variation in plasma. Arteriosclerosis, Thrombosis and Vascular Biology. 16:1996;72-76.
96. Pollak E S, Hung H L, Godin W. Functional characterization of the human factor VII 5′-flanking region. Journal of Biological Chemistry. 271:1996;1738-1747.
97. Humphries S E, Lane E, Green F R. Factor VII coagulant activity and antigen levels in healthy men are determined by interaction between factor VII genotype and plasma triglyceride concentration. Arteriosclerosis and Thrombosis. 14:1994;193-198.
98. Hong Y, Pedersen N L, Egberg N, de Faire U. Genetic effects for plasma factor VII levels independent of and in common with triglycerides. Thrombosis and Haemostasis. 81:1999;382-386.
99. Mennen L I, de Maat M PM, Schouten E G. Coagulation factor VII, serum-triglycerides and the R/Q353 polymorphism: differences between older men and women. Thrombosis and Haemostasis. 78:1997;984-986.
100. Doggen C JM, Cats V M, Bertina R M. A genetic propensity to high factor VII is not associated with the risk of myocardial infarction in men. Thrombosis and Haemostasis. 80:1998;281.
101. Iacoviello L, Di Castelnuovo A, de Knijff P. Polymorphisms in the coagulation factor VII gene and the risk of myocardial infarction. New England Journal of Medicine. 338:1998;79-85.
102. Heywood D M, Carter A M, Catto A J. Polymorphisms of the factor VII gene and circulating FVII:C levels in relation to acute cerebrovascular disease and poststroke mortality. Stroke. 28:1997;816-821.
103. Booth N A. The natural inhibitors of fibrinolysis. Bloom A L. Haemostasis and Thrombosis. 1994;699-720 Churchill Livingstone, Edinburgh.
104. Torr-Brown S R, Sobel B E. Attenuation of thrombolysis by release of plasminogen activator inhibitor type-1 from platelets. Thrombosis Research. 72:1993;413-421.
105. Lupu F, Bergonzelli G E, Heim D A. Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arteriosclerosis, Thrombosis and Vascular Biology. 13:1993;1090-1100.
106. Sobel B E, Woodcock-Mitchell J, Schneider D J. Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with non-diabetic patients. A potential factor predisposing to thrombosis and its persistence. Circulation. 97:1998;2213-2221.
107. Wiman B, Ljungberg B, Chmielewska J. The role of the fibrinolytic system in deep vein thrombosis. Laboratory and Clinical Medicine. 105:1985;265-270.
108. Auwerx J, Bouillon R, Collen D, Gebeors J. Tissue type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mel;litus. Arteriosclerosis. 8:1988;68-72.
109. Margaglione M, Di Minno G, Grandone E. Abnormally high circulation levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in patients with a history of ischemic stroke. Arteriosclerosis, Thrombosis and Vascular Biology. 14:1994;1741-1745.
110. Thogersen A M, Jansson J-H, Boman K. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women. Evidence for the fibrinolytic system as an independent primary risk factor. Circulation. 98:1998;2241-2247.
111. Emeis J, Kooistra T. Interleukin-1 and lipopolysaccharide induce a fast acting inhibitor of tissue-type plasminogen activator in vivo and in cultured endothelial cells. Journal of Experimental Medicine. 163:1986;1260-1266.
112. Lund L, Riccio A, Andreasen P. Transforming growth factor-beta is a strong and fast acting positive regulator of the level of type-1 plasminogen activator inhibitor mRNA in WI-38 human lung fibroblasts. EMBO Journal. 6:1987;1281-1286.
113. Alessi M, Juhan-Vague I, Kooistra T. Insulin stimulates the synthesis of plasminogen activator inhibitory by the human hepatocellular cell line HepG2. Thrombosis and Haemostasis. 60:1988;491-494.
114. Lucore C, Fuji S, Wun T. Regulation of the expression of type 1 plasminogen activator inhibitor in HepG2 cells by epidermal growth factor. Journal of Biological Chemistry. 263:1988;15845-15848.
115. Riccio A, Lund L, Sartorio R. The regulatory region of the human plasminogen activator inhibitor type-1 gene. Nucleic Acids Research. 16:1988;2805-2824.
116. Stiko-Rahm A, Wiman B, Hamsten A, Nilsson J. Secretion of plasminogen activator inhibitory from human umbilical vein endothelial cells is induced by very low density lipoprotein. Arteriosclerosis. 10:1990;1067-1073.
117. De Boer J, Abbnik J, Brouwer M. PAI-1 synthesis in the human hepatoma cell line HepG2 is increased by cytokines - evidence that the liver contributes to acute phase behaviour of PAI-1. Thrombosis and Haemostasis. 65:1991;181-187.
118. Juhan-Vague I, Alessi M C, Vague P. Increased plasma plasminogen activator inhibitor 1 levels: a possible link between insulin resistance and atherothrombosis. Diabetologia. 34:1991;457-462.
119. Juhan-Vague I, Thompson S G, Jespersen J. Involvement of the hemostatic system in the insulin resistance syndrome: a study of 1,500 patients with angina pectoris. Arteriosclerosis, Thrombosis and Vascular Biology. 13:1993;1865-1873.
120. Mansfield M W, Stickland M H, Grant P J. PAI-1 concentrations in first degree relatives of patients with non-insulin-dependent diabetes mellitus: metabolic and genetic associations. Thrombosis and Haemostasis. 77:1997;357-361.
121. Klinger K, Winqvist R, Riccio A. Plasminogen activator inhibitor type 1 gene is located at region q21.3-q22 of chromosome 7 and genetically linked with cystic fibrosis. Proceedings of the National Academy of Sciences of the USA. 84:1987;8548-8552.
122. Bosma P J, van den Berg E A, Kooistra T. Human plasminogen activator inhibitory gene. Promoter and structural gene nucleotide sequences. Journal of Biological Chemistry. 263:1988;9129-9141.
123. Mehta J, Mehta P, Lawson D, Saldeen T. Plasma tissue plasminogen activator inhibitor levels in coronary artery disease. Correlation with age and serum triglyceride concentrations. Journal of the American College of Cardiology. 9:1987;263-268.
124. Juhan-Vague I, Alessi M C, Badier C. Relationship between plasma insulin, triglyceride, body mass index and plasminogen activator inhibitor-1. Diabetes and Metabolism. 13:1987;331-336.
125. Juhan-Vague I, Alessi M, Joly P. Plasma plasminogen activator inhibitor 1 in angina pectoris: Influence of plasma insulin and acute phase response. Arteriosclerosis. 9:1989;362-367.
126. Ye S, Green F R, Scarabin P Y. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Thrombosis and Haemostasis. 74:1995;837-841.
127. Ossei-Gerning N, Mansfield M W, Stickland M H. Plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G genotype and levels in relation to a history of myocardial infarction in patients characterised by coronary angiography. Arteriosclerosis, Thrombosis and Vascular Biology. 17:1997;33-37.
128. Eriksson P, Kallin B, van't Hooft F M. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proceedings of the National Academy of Sciences of the USA. 92:1995;1851-1855.
129. Burzotta F, di Castelnuovo A, Amore C. 4G/5G promoter PAI-1 gene polymorphism is associated with plasmatic PAI-1 activity in Italians: a model of gene-environment interaction. Thrombosis and Haemostasis. 79:1998;354-358.
130. Stegnar M, Uhrin P, Peternel P. The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: relationship to plasma PAI-1 level in venous thromboembolism. Thrombosis and Haemostasis. 79:1998;975-979.
131. Margaglione M, Grandone E, Vecchione G. Plasminogen activator inhibitor-1 (PAI-1) antigen plasma levels in subjects attending a metabolic ward: relation to polymorphisms of PAI-1 and angiotensin converting enzyme (ACE) genes. Arteriosclerosis, Thrombosis and Vascular Biology. 17:1997;2082-2087.
132. Panahloo A, Mohamed-Ali V, Lane A. Determinants of plasminogen activator inhibitor-1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor-1 gene. Diabetes. 44:1995;37-42.
133. Mansfield M W, Stickland M H, Grant P J. Environmental and genetic factors in relation to elevated circulating levels of plasminogen activator inhibitor-1 in Caucasian patients with non-insulin-dependent diabetes mellitus. Thrombosis and Haemostasis. 74:1995;842-847.
134. Eriksson P, Nilsson L, Karpe F, Hamsten A. Very-low-density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia. Arteriosclerosis, Thrombosis and Vascular Biology. 18:1998;20-26.
135. Vaisanen S B, Humphries S E, Lunong L-A. Regular exercise, plasminogen activator inhibitor-1 (PAI-1) activity and the 4G/5G promoter polymorphism in the PAI-1 gene. Thrombosis and Haemostasis. 82:1999;1117-1120.
136. Cesari M, Sartori M T, Patrassi G M. Determinants of plasma levels of plasminogen activator inhibitor-1: A study of normotensive twins. Arteriosclerosis, Thrombosis and Vascular Biology. 19:1999;316-320.
137. Henry M, Chomiki N, Scarabin P Y. Five frequent polymorphisms of the PAI-1 gene: lack of association between genotypes, PAI activity, and triglyceride levels in a healthy population. Arteriosclerosis, Thrombosis and Vascular Biology. 17:1997;851-858.
138. Henry M, Tregouet D A, Alessi M C. Metabolic determinants are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concentrations: a family study with part of the Stanislas Cohort. Arteriosclerosis, Thrombosis and Vascular Biology. 18:1998;84-91.
139. Mansfield M W, Stickland M H, Grant P J. Plasminogen activator inhibitor-1 promoter polymorphism and coronary artery disease in non-insulin dependent diabetes. Thrombosis and Haemostasis. 74:1995;1032-1034.
140. Margaglione M, Cappucci G, Colaizzo D. The PAI-1 gene locus 4G/5G polymorphism is associated with a family history of coronary artery disease. Arteriosclerosis, Thrombosis and Vascular Biology. 18:1998;152-156.
141. Iwai N, Shimoike H, Nakamura Y. The 4G/5G polymorphism of the plasminogen activator inhibitor gene is associated with the time course of progression to acute coronary syndromes. Atherosclerosis. 136:1998;109-114.
142. Ridker P M, Hennekens C H, Lindpaintner K. Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men. Circulation. 95:1997;59-62.
143. Gardemann A, Lohre J, Katz N. The 4G4G genotype of the plasminogen activator inhibitor 4G/5G gene polymorphisms is associated with coronary atherosclerosis in patients at high risk for this disease. Thrombosis and Haemostasis. 82:1999;1121-1126.
144. Catto A J, Carter A M, Stickland M H. Plasminogen activator inhibitor-1 4G/5G promoter polymorphism and levels in subjects with cerebrovascular disease. Thrombosis and Haemostasis. 77:1997;730-734.
145. Iacoviello L, Burzotta F, Di Castelnuovo A. The 4G/5G polymorphism of PAI-1 promoter gene and the risk of myocardial infarction: a meta-analysis. Thrombosis and Haemostasis. 80:1998;1029-1030.
146. Ichinose A. The physiology and biochemistry of factor XIII. Bloom A L, Forbes C D, Thomas D P, Tuddenham E GD. Haemostasis and Thrombosis. 1994;531-548 Churchill Livingstone, Edinburgh.
147. Shebuski R J, Sitko G R, Claremon D A. Inhibition of factor XIIIa in a canine model of coronary thrombosis: effect of reperfusion and acute reocclusion after recombinant tissue-type plasminogen activator. Blood. 76:1990;1455-1459.
148. Reed G L, Houng A K. The contribution of activated Factor XIII to fibrinolytic resistance in experimental pulmonary embolus. Circulation. 99:1999;299-304.
149. Tuddenham E GD, Cooper D N. Factor XIII. Tuddenham E GD, Cooper D N. The Molecular Genetics of Haemostasis and its Inherited Disorders. 1994;271-283 Oxford University Press, Oxford.
150. Suzuki K, Iwata M, Ito S. Molecular basis for subtype differences of the 'a' subunit of coagulation factor XIII with description of the genesis of the subtypes. Human Genetics. 94:1994;129-135.
151. Anwar R, Stewart A D, Miloszewski K JA, Losowsky M S. Molecular basis of inherited factor XIII deficiency: identification of multiple mutations provides insights into protein function. British Journal of Haematology. 91:1995;728-735.
152. Mikkola H, Syrjala M, Rasi V. Deficiency in the A-subunit of coagulation factor XIII: two novel point mutations demonstrate different effects on transcript levels. Blood. 84:1994;517-525.
153. Suzuki K, Henke J, Iwata M. Novel polymorphisms and haplotypes in the human coagulation factor XIII A-subunit gene. Human Genetics. 98:1996;393-395.
154. Kohler H P, Grant P J. Clustering of haemostatic risk factors with FXIIIVal34Leu in patients with myocardial infarction. Thrombosis and Haemostasis. 80:1998;862.
155. Kohler H P, Mansfield M W, Clark P S, Grant P J. Interaction between insulin resistance and Factor XIIIVal34Leu in patients with coronary artery disease. Thrombosis and Haemostasis. 82:1999;1202-1203.
156. Kohler H P, Futers T S, Grant P J. Prevalence of three common polymorphisms in the a-subunit gene of factor XIII in patients with coronary artery disease: association with FXIII activity and antigen levels. Thrombosis and Haemostasis. 81:1999;511-515.
157. Wartiovaara U, Perola M, Mikkola H. Association of FXIII Val34Leu with decreased risk of myocardial infarction in Finnish males. Atherosclerosis. 142:1999;295-300.
158. McCormack L, Kain K, Catto A J. Prevalence of FXIII V34L in populations with different cardiovascular risk. Thrombosis and Haemostasis. 80:1998;523-524.
159. Kangsadalampai S, Board P G. The Val34Leu polymorphism in the A subunit of coagulation Factor XIII contributes to the large normal range in activity and demonstrates that the activation peptide plays a role in catalytic activity. Blood. 92:1998;2766-2770.
160. Catto A J, Kohler H P, Coore J. Association of a common polymorphism in the Factor XIII gene with venous thrombosis. Blood. 93:1999;906-908.
161. Franco R F, Reitsma P H, Lourenco D. Factor XIII Val34Leu is a genetic factor involved in the aetiology of venous thrombosis. Thrombosis and Haemostasis. 81:1999;676.
162. Catto A J, Kohler H P, Bannan S. Factor XIIIVal34Leu: a novel association with primary intracerebral haemorrhage. Stroke. 29:1998;813-816.
163. Ruggeri Z M. New insights into the mechanisms of platelet adhesion and aggregation. Seminars in Hematology. 31:1994;229-239.
164. Bray P F. Inherited diseases of platelet glycoproteins: considerations for rapid molecular characterisation. Thrombosis and Haemostasis. 72:1994;492-502.
165. Lincoff A M. Trials of platelet glycoprotein IIb/IIIa receptor antagonists during percutaneous coronary revascularization. American Journal of Cardiology. 82:1998;36P-42P.
166. Ruggeri Z M. New insights into the mechanisms of platelet adhesion and aggregation. Seminars in Hematology. 31:1994;229.
167. Newman P J. Platelet alloantigens: cardiovascular as well as immunological risk factors. Lancet. 349:1997;370-371.
168. Goldschmidt-Clermont P J, Shear W S, Schwartzberg J. Clues to the death of an Olympic champion. Lancet. 348:1996;485-486.
169. Ridker P M, Hennekens C H, Schmitz C. P1A1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke and venous thrombosis. Lancet. 349:1997;385-388.
170. Herrmann S M, Poirier O, Marques-Vidal P. The Leu 33/Pro polymorphism (P1A1/P1A2) of the glycoprotein IIIa (GPIIIa) receptor is not related to myocardial infarction in the ECTIM Study. Thrombosis and Haemostasis. 77:1997;1179-1181.
171. Carter A M, Ossei-Gerning N, Wilson I J, Grant P J. Association of the platelet P1(A) polymorphism of glycoprotein IIb/IIIa and the fibrinogen Bβ448 polymorphism with myocardial infarction and extent of coronary artery disease. Circulation. 96:1997;1424-1431.
172. Samani N J, Lodwick D. Glycoprotein IIIa polymorphism and risk of myocardial infarction. Cardiovascular Research. 33:1997;693-697.
173. Marian A J, Brugada R, Kleiman N S. Platelet glycoprotein IIIa P1A polymorphism and myocardial infarction. New England Journal of Medicine. 334:1996;1071-1072.
174. Durante-Mangoni E, Davies G J, Ahmed N. Coronary thrombosis and the platelet glycoprotein IIIA gene P1A2 polymorphism. Thrombosis and Haemostasis. 80:1998;218-219.
175. Carter A M, Ossei-Gerning N, Grant P J. Platelet glycoprotein IIIa P1A polymorphism in young men with myocardial infarction. Lancet. 347:1996;1833.
176. Gardemann A, Humme J, Stricker J. Association of the platelet glycoprotein IIIa P1A1/A2 gene polymorphism to coronary artery disease but not to nonfatal myocardial infarction in low risk patients. Thrombosis and Haemostasis. 80:1998;214-217.
177. Mamotte C D, van Bockxmeer F M, Taylor R R. P1A1/A2 polymorphism of glycoprotein IIIa and risk of coronary artery disease and restenosis following coronary angioplasty. American Journal of Cardiology. 82:1998;13-16.
178. Zotz R B, Winkelmann B R, Nauck M. Polymorphism of platelet membrane glycoprotein IIIa: human platelet antigen Ib (HPA-Ib/P1A2) is an inherited risk factor for premature myocardial infarction in coronary artery disease. Thrombosis and Haemostasis. 79:1998;731-735.
179. Walter D H, Schachinger V, Elsner M. Platelet glycoprotein IIIa polymorphisms and risk of coronary stent thrombosis. Lancet. 350:1997;1217-1219.
180. Carter A M, Catto A J, Bamford J M, Grant P J. Platelet GpIIIa P1A and GpIb variable number tandem repeat polymorphisms and markers of platelet activation in acute stroke. Arteriosclerosis, Thrombosis and Vascular Biology. 18:1998;1124-1131.
181. Carlsson L E, Greinacher A, Spitzer C. Polymorphisms of the human platelet receptors for fibrinogen (GPIIb/IIIa), von Willebrand factor (GPIb/IX) and collagen (GPIa/IIa) are not correlated with an increased risk for stroke. Stroke. 28:1997;1392-1395.
182. Ridker P M, Vaughan D E, Stampfer M J. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet. 341:1993;1165-1168.
183. Jansson J H, Nilsson T K, Johnson O. Von Willebrand factor, tissue plasminogen activator and dehydroepiandrosterone predict cardiovascular death in a 10 year follow up of survivors of acute myocardial infarction. Heart. 80:1998;334-337.
184. Kanaji T, Okamura T, Osaki K. A common genetic polymorphism (46C to T substitution) in the 5′ untranslated region of the coagulation Factor XII gene is associated with low translation efficiency and decrease in Factor XII level. Blood. 91:1998;2010-2014.
185. Kohler H P, Futers T S, Grant P J. FXII (46CT) polymorphism and in-vivo generation of Factor XII activity. Thrombosis and Haemostasis. 81:1999;745-747.